Clinical trial NCT06165822: A Study to Evaluate Drug-Drug Interaction of TQB3909 Tablets
Official title: A Phase I Study to Evaluate Drug-Drug Interaction of TQB3909 Tablets
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE1
Conditions: Advanced Malignant Neoplasm
Keywords: Drug drug interaction
Lead sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2023-12-12
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a single-center, open, single-dose, self-controlled phase I clinical trial to evaluate the effects of Itraconazole Capsules/Rifampicin Capsules on pharmacokinetics of TQB3909 tablets in vivo, and the safety of TQB3909 tablets and combined with Itraconazole Capsules/Rifampicin Capsules after single oral dose.


Eligibility criteria: Inclusion Criteria:

* At the time of signing the informed consent, males or females of between 18 and 45 years of age;
* Female weight ≥45 kg, male weight ≥50 kg, with a body mass index (BMI) between 19 and 26 kg/m2.
* Subjects in good health, as determined by a medical history, vital signs, physical examination, 12-lead electrocardiogram (ECG) and clinical laboratory evaluations;
* Subjects can comply with the study procedures, voluntarily participate in the study, and sign the informed consent in person.

Exclusion Criteria:

* Subjects: pre-existing or existing circulatory system, endocrine system, nervous system, digestive system, respiratory system, genitourinary system, hematology, immunology, psychiatry and metabolic disorders mental diseases or abnormalities, or related chronic or acute diseases, which were not appropriate to participate in the trial as assessed by the investigators ;
* Subjects with systemic/local acute infection presented before study drug administration;
* Subjects who have a history of specific allergies, or allergies;
* Subjects who have difficulty in swallowing or have any gastrointestinal disorder that affects drug absorption at the time of screening；
* Subjects who cannot receive venous indwelling needle for blood sample collection；
* Subjects who cannot tolerate venous puncture or have a history of needle or blood sickness;
* Subjects who drank regularly within the 6 months prior to the first dosing, such as those who drank more than 14 units of alcohol per week or who had a positive alcohol breath test at the time of screening；
* Subjects who had a history of major surgery, had taken the study drug, or had participated in other drug clinical trials within 3 months prior to the first dosing；
* Subjects who donated blood or lost significant amounts of blood within 3 months prior to the first dosing；
* Subjects who had used drugs within 3 months prior to the first dosing, or tested positive for drugs, or had a history of drug abuse within 5 years prior to screening；
* Subjects who smoked more than 5 cigarettes per day within the 3 months prior to the first dosing or who could not stop using any tobacco products during the trial；
* Subjects who consumed excessive amounts of tea, coffee, and/or caffeinated beverages daily within the 30 days prior to the first dosing；
* Subjects who have used any drug that inhibits or induces liver metabolism of the drug within the 30 days prior to the first dosing；
* Subjects who have taken any prescription, over-the-counter, herbal, or health product within the 14 days prior to the first dosing；
* Subjects who have taken a special diet or other factors affecting drug absorption, distribution, metabolism, or excretion within 7 days prior to the first dosing；
* Subjects who ingested chocolate, any caffeinated, or xanthine-rich food or drink within 48 hours before the first dosing；
* Subjects who have special dietary requirements and cannot follow a uniform diet；
* Female subjects of child-bearing potential；
* Subjects judged by the investigators to be unsuitable to participate.

Primary outcomes:
measure: Time to Reach Maximum Observed Plasma Concentration (Tmax)
timeFrame: Inhibitor group: pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 14, 24, 48, 72 hours (only on Day 8) after dose on Day 1 and Day 8. Inducer group: pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 14, 24, 48 hours after dose on Day 1 and Day 10.
measure: Maximum Plasma Concentration (Cmax)
timeFrame: Inhibitor group: pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 14, 24, 48, 72 hours (only on Day 8) after dose on Day 1 and Day 8. Inducer group: pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 14, 24, 48 hours after dose on Day 1 and Day 10.
measure: Elimination half-life (t1/2)
timeFrame: Inhibitor group: pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 14, 24, 48, 72 hours (only on Day 8) after dose on Day 1 and Day 8. Inducer group: pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 14, 24, 48 hours after dose on Day 1 and Day 10.
Secondary outcomes:
measure: Incidence of adverse events (AEs)
timeFrame: Up to 12 days.
Other outcomes:
Locations:
city: Changzhou
country: China
facility: The First People's Hospital of Changzhou
state: Jiangsu
Study officials:
References: